Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Integrated Consent Model for Febrile Neutropenia Prophylaxis in Breast Cancer
NCT02173262Phase 4Completed
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Aug 2014
- Primary completion
- Sep 2017
- Modality
- Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of filgrastim, ciprofloxacin in febrile neutropenia (FN), sponsored by Ottawa Hospital Research Institute. Started Aug 2014; status: completed.
02
Drugs
filgrastimciprofloxacin
03
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on NCT02173262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02173262.